Friday, 16 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· October 31, 2025

Chevron Reports Third Quarter 2025 Results

View original at finance.yahoo.com
Chevron Reports Third Quarter 2025 Results Reported earnings of $3.5 billion; adjusted earnings of $3.6 billion Record production of 4.1 million BOE per day; 21 percent higher than last year Cash flow from operations of $9.4 billion; adjusted free cash flow of $7.0 billion HOUSTON, October 31, 2025--(BUSINESS WIRE)--Ch…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The integration of Hess is progressing well, unlocking synergies across our operations and positioning Chevron as a premier global energy company

    80% confidence

  • Third quarter results reflect record production, strong cash generation and sustained superior cash returns to shareholders

    80% confidence

  • U.S. and worldwide production hit new company records, up 27 percent and 21 percent, respectively, from last year

    80% confidence

  • The company returned $6 billion of cash to shareholders in the quarter, and over $78 billion in the last 3 years

    80% confidence

  • Strong cash flow from operations was sustained while the company's adjusted free cash flow increased more than 50 percent from a year ago

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com
Chevron Reports Third Quarter 2025 Results — Source | Via News | ViaNews EU